Applied Therapeutics, Inc.
APLT
$0.4601
-$0.0288-5.89%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 122.00K | 144.00K | 190.00K | -667.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 122.00K | 144.00K | 190.00K | -667.00K | -- |
| Cost of Revenue | 14.83M | 10.00M | 12.22M | 53.91M | 10.79M |
| Gross Profit | -14.71M | -9.86M | -12.03M | -54.57M | -10.79M |
| SG&A Expenses | 15.04M | 10.58M | 9.07M | 5.04M | 4.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.87M | 20.58M | 21.28M | 20.34M | 15.50M |
| Operating Income | -29.74M | -20.44M | -21.09M | -21.01M | -15.50M |
| Income Before Tax | -68.59M | 2.90M | -83.94M | -37.68M | -42.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.59M | 2.90M | -83.94M | -37.68M | -42.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.59M | 2.90M | -83.94M | -37.68M | -42.37M |
| EBIT | -29.74M | -20.44M | -21.09M | -21.01M | -15.50M |
| EBITDA | -29.74M | -20.44M | -21.09M | -21.01M | -15.50M |
| EPS Basic | -0.48 | 0.02 | -0.67 | -0.34 | -0.47 |
| Normalized Basic EPS | -0.30 | 0.01 | -0.42 | -0.21 | -0.29 |
| EPS Diluted | -0.48 | -0.13 | -0.67 | -0.34 | -0.47 |
| Normalized Diluted EPS | -0.30 | 0.01 | -0.42 | -0.21 | -0.29 |
| Average Basic Shares Outstanding | 144.35M | 143.93M | 125.32M | 110.53M | 90.67M |
| Average Diluted Shares Outstanding | 144.35M | 152.39M | 125.32M | 110.53M | 90.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
